Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPH - Cytoclonal Pharmaceutics -- Ignore unavailable to you. Want to Upgrade?

To: sks1 who wrote (109)	3/20/1998 5:41:00 PM
From: Candle stick	Respond to of 428

The market for Taxol just got much bigger....... FDA panel backs Bristol<BMY.N> drug for ovary canc BETHESDA, Md., March 20 (Reuters) - An advisory panel voted unanimously on Friday to recommend U.S. Food and Drug Administration approval of Bristol-Myers Squibb Co.'s Taxol (paclitaxel), in combination with another drug, as a first-line therapy for advanced ovarian cancer. The FDA generally follows the advice of its panels. The Taxol/cisplatin combination delays disease worsening and lengthens lives, the panel said. MORE Rtr 10:56 03-20-98 AND THIS....... FDA panel backs Bristol<BMY.N> lung cancer drug WASHINGTON, March 20 (Reuters) - Federal advisers voted on Friday to recommend U.S. Food and Drug Administration (FDA) approval of Bristol-Myers Squibb's Taxol (paclitaxel), in combination with another drug, for treatment of advanced non-small cell lung cancer (NSCLC). "I am persuaded there is a modest survival advantage," panelist Richard Schilsky of the University of Chicago Cancer Research Center said of the paclitaxel/cisplatin combination. "I'm also persuaded there is some quality of life advantage to this therapy." The FDA generally follows its panels advice. MORE Rtr 15:37 03-20-98 These CYPH patents should be worth a lot more now.........;^)